Our business was introduced in ThermoFisher Scientific's life science magazine "NEXT" No.67.
We are pleased to inform you that Thermo Fisher Scientific's life science magazine "NEXT" No.67, digitally published on October 25, 2023, features an introduction to our business titled "Diversified development of contract services and collaborative research with our unique genome editing and nucleic acid delivery technologies" Click here for the digital issue in Japanese.
Our President Dr. Sugo's review article is published in the October issue of Hokuryukan's "BIO Clinica" in Japanese.
His review "Propriety Nucleic Acid Delivery Technologies for Realizing a New Therapeutic Modality" is one of the topics for "Research and development of disease therapies using iPS cells" in the October issue published on September 25th, 2023. Click here for the summary of the review in English.
Notice about Decision of a Patent Grant
GenAhead Bio Inc. has been granted a patent for nucleic acid delivery technology in Japan. Click here for the press release
GenAhead Bio licenses CRISPR/Cas9 from Broad Institute
GenAhead Bio Incorporated ("GenAhead") announced today the signing of a non-exclusive commercial research tool and services license agreement to CRISPR / Cas9 genome editing technology from the Broad Institute of MIT and Harvard. GenAhead began operations in 2018 as a spin-out from Takeda Pharmaceutical Company Limited and has since leveraged the latest CRISPR / Cas9 […]
Our highly efficient genome editing technology, CRISPR-SNIPER, was featured in the following article in "Bioradiations"
Our highly efficient genome editing technology, CRISPR-SNIPER, was featured in the following article in "Bioradiations". Title of the article: “Modernizing Gene Editing Detection with Droplet Digital PCR”
Research Project for the Promotion of Innovative Drug Development for Emerging and Re-emerging Infectious Diseases
We are pleased to announce that our proposal has been selected by the Japan Agency for Medical Research and Development (AMED) for the third round of the "Research Project for Promoting Innovative Drug Development for Emerging and Re-emerging Infectious Diseases" in FY2022. The press release can be found here
GenAhead Bio Selected as a Grantee for the Fifth Business Restructuring Subsidy
We are pleased to announce that GenAhead Bio has been selected as a recipient of the "Business Restructuring Subsidy" by the Small and Medium Enterprise Agency. Click here to see the press release.